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Experimental heart transplantation: effect of cyclosporine on
expression and activity of metzincins
Abstract
Metzincins, such as matrix metalloproteases (MMP), and extracellular matrix (ECM) proteins are
differentially regulated in inflammation. We hypothesised that metzincins are also dysregulated in
experimental acute cardiac allograft rejection. We investigated the Dark Agouti-to-Lewis (DA-to-Lew)
rat model of acute cardiac allograft rejection. Cyclosporine (CsA) (7.5 mg/kg/d) was given from
transplantation to sacrifice (day +5). At that time, mRNA levels were analysed by Affymetrix genechip
and quantitative reverse transcription polymerase chain reaction (qRTPCR). MMP protein and activities
were analysed by immunohistology, fluorometry, zymography and Western blots. In untreated rejected
DA allografts, mRNA levels of MMP-2/-7/-9/-/12-/14, a disintegrin and metalloprotease (ADAM)-17,
tissue inhibitor of metalloprotease (TIMP)-1/-3 were increased, whereas MMP-11/-16/-24 and
TIMP-2/-4 were lowered compared to native DA hearts. With respect to these untreated allografts, CsA
lowered mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-4 remained relatively low) and ADAM17, but
augmented mRNA levels of MMP-11/-16/-23 and of many ECM genes. Immunohistology showed
increased staining of MMP-2 in acute rejection (AR). Overall MMP activity was augmented in both
transplanted groups, but CsA reduced MMP-9 activity and MMP-14 production. Taken together, MMP
and TIMP were upregulated during acute AR. CsA ameliorated histology of rejection but showed
potential pro-fibrotic effects. Thus, MMP and TIMP may play a role in acute cardiac allograft rejection,
and beneficial modification of the MMP-ECM balance requires interventions beyond CsA.
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Metzincins, such as matrix metalloproteases
(MMP), and extracellular matrix (ECM) proteins
are differentially regulated in inflammation. We
hypothesised that metzincins are also dysregu-
lated in experimental acute cardiac allograft rejec-
tion.
We investigated the Dark Agouti-to-Lewis
(DA-to-Lew) rat model of acute cardiac allograft
rejection. Cyclosporine (CsA) (7.5 mg/kg/d) was
given from transplantation to sacrifice (day +5). At
that time, mRNA levels were analysed by
Affymetrix genechip and quantitative reverse
transcription polymerase chain reaction (qRT-
PCR). MMP protein and activities were analysed
by immunohistology, fluorometry, zymography
andWestern blots.
In untreated rejected DA allografts, mRNA
levels of MMP-2/-7/-9/-/12-/14, a disintegrin
and metalloprotease (ADAM)-17, tissue inhibitor
of metalloprotease (TIMP)-1/-3 were increased,
whereas MMP-11/-16/-24 and TIMP-2/-4 were
lowered compared to native DA hearts. With re-
spect to these untreated allografts, CsA lowered
mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-
4 remained relatively low) and ADAM17, but aug-
mented mRNA levels of MMP-11/-16/-23 and of
many ECM genes. Immunohistology showed in-
creased staining of MMP-2 in acute rejection
(AR). Overall MMP activity was augmented in
both transplanted groups, but CsA reduced
MMP-9 activity and MMP-14 production.
Taken together, MMP and TIMP were up-
regulated during acute AR. CsA ameliorated his-
tology of rejection but showed potential pro-fi-
brotic effects. Thus, MMP and TIMP may play a
role in acute cardiac allograft rejection, and bene-
ficial modification of the MMP-ECM balance re-
quires interventions beyond CsA.
Key words: cardiac allograft; acute rejection; ex-
tracellular matrix (ECM); matrix metalloproteinases
(MMP); rat transplant model; transcriptomics
Summary
1
Heart transplantation remains the optimal
life-saving procedure for patients with advanced
cardiac failure. The success of this therapeutic
modality is still marred by the occurrence of re-
jection episodes and allograft fibrosis or sclerosis
as common final pathways of immunologic and
non-immunologic origin, despite modern im-
munosuppressive therapy [1, 2]. Thus, elucidation
of the pathophysiology of acute cardiac allograft
rejection and the potential fibrogenic influence of
key immunosuppressive agents, especially cy-
closporine (CsA), continue to be very important
for clinical transplant medicine.
Inflammatory processes in solid organs are to
a significant extent controlled by the metzincin
superfamily of metallo-endopeptidases, mainly
matrix metalloproteinases (MMP), adamalysins
(ADAM) and meprin [3–5].
MMP were in the focus of this project as the
best characterized group of metzincins. These
proteases are traditionally classified into four cat-
egories, consisting of interstitial collagenases
(MMP-1/-8/-13), gelatinases (MMP-2/-9),
stromelysins (MMP-3/-7/-10/-11/-12) and mem-
brane-type (MT)-MMP (MMP-14, -15, -16, -17,
-24, and -25) [3,6]. The majority of MMP are se-
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Introduction
creted in a latent proenzyme form and requires
extracellular activation [3]. Naturally, MMP inhi-
bition occurs by tissue inhibitors of metallopro-
teinases (TIMP1-3) [3]. MMP activity can also be
inhibited by a spectrum of low molecular weight,
both peptide- and nonpeptide-based synthetic
MMP inhibitors [7].
The main functions of MMP consist in the
degradation of extracellular matrix (ECM) pro-
teins, and to a somewhat lesser extent in the regu-
lation of cell proliferation [8]. MMP are increas-
ingly recognized as important pro-inflammatory
mediators [3, 8–9]. In transplantation, MMP may
act as pro-inflammatory mediators in several
ways: direct tissue injury, augmentation of cell
proliferation and/or migration and facilitation of
tissue invasion by extrinsic cells (e.g., leukocytes)
[8, 10].
The purpose of the present investigations was
to examine the effect of CsA on the expression of
metzincins, mainly MMP andTIMP, and in a lim-
ited fashion of their substrates in an established
rodent model of heart transplantation.
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Metzincins and CsA in acute heart allograft rejection
Materials and methods
Animals and heart transplantation
Heterotopic cardiac grafting was performed in the
laboratories of Novartis Pharma AG, Basel, Switzerland,
using the Dark Agouti-to-Lewis (DA-to-Lew) rat strain
combination, as published previously [10]. Two groups of
hearts were studied at the time of sacrifice, day +5 after
transplantation: untreated DA allografts and CsA treated
DA allografts (Neoral, 7.5 mg/kg/day, given from trans-
plantation to sacrifice at day +5). Additionally, native
hearts from healthy DA rats served as controls (n = 6 in
each group). The study was performed according to the
Swiss federal law on animal protection and approved by
the Basel Veterinary Office.
Biochemical analyses
Biochemical serum analyses were performed using
the Beckmann Synchron CX-5 automatic chemistry
analyzer.
Total protein and RNA extractions
Frozen hearts were first homogenised as powder in
liquid nitrogen. Subsequently, proteins and total RNA
were isolated according to the manufacturer’s instructions
(PARIS
TM
kit, AMBION INC). All aliquots of samples
were stored at –70 °C until use. Protein concentration
was determined using the BCA
TM
Protein Assay
(PIERCE). RNA concentration was measured using a
spectrophotometer and the quality was analysed by Bio-
analyzer 2100 electropherograms (Agilent Technologies).
Genechip expression analysis
Affymetrix Rat Genome 230 2.0 Arrays were used
according to the manufacturer’s instructions, as previ-
ously described by us [12].
Hierarchical clustering
Hierarchical cluster was performed using dChip-
software (http://biosun1.harvard.edu/ complab/dChip/).
The clustering algorithm applied the “1-Pearson correla-
tion coefficient” for the distance metric and the “cen-
troid-linkage” method using clustering and gene function
enrichment.
Quantitative reverse transcription polymerase chain
reaction analysis (qRT-PCR)
Real time qRT-PCR analyses were performed as de-
scribed previously [12]. Assays-on-demand gene expres-
sion products were used according to manufacturer’s pro-
tocol (Applied Biosystems).
Zymography of MMP-2/-9 and fluorometry of MMP
activity
MMP activity in protein extractions (see above) from
frozen tissue homogenates was analyzed by gelatin sub-
strate zymography (MMP-9) and by fluorometry (overall
MMP activity), as previously described by us [12].
Western blot analysis for MMP-2/-9/-14 andTIMP-2
Western blot analyses were performed as previously
described [12], using anti-MMP-2 (468-483) (Ab-3)
human (mouse) (1:100), anti-MMP-9 (626-644) (Ab-3)
human (mouse) (1:100), anti-MMP-14 (Ab-4) human
(mouse) (1:25), anti-TIMP-2 (Ab-2) mouse mAb (67-
4H11) (1:50) and as secondary antibody the peroxidase
goat anti-mouse IgG. All antibodies are from Cal-
biochem.
Immunohistology of MMP-2
Immunohistology of MMP-2 was performed using
rat heart sections, exactly as described previously, using
the anti-MMP-2 (Ab-3) clone A-Gel VC2 from Neo-
markers [12].
Statistics
All the investigations (qRT-PCR, immunohistology,
etc.) were not done blinded to the type of rat (healthy, un-
treated, CsA-treated). The sample size was selected ac-
cording to our resources. Results are presented as means
± standard error of mean (SEM) and were analyzed by
non-parametric Mann-Whitney test using the GraphPad
Prism Software version 4.0 for Windows. The analysis of
MAS5 normalised genechip expression values was per-
formed using GeneSpring 6.1.1 (Silicon Genetics). A
probability of error (p-value) <0.05 (two-sided) was con-
sidered significant.
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Histological and biochemical characterization
of cardiac allograft rejection
As expected, untreated cardiac allografts
showed histological signs of severe acute rejection
(AR) 5 days after transplantation (maximum sur-
vival time of untreated transplanted animals)
(table 1a). Treatment with CsA reduced the sever-
ity of the AR, chiefly reflected in a decrease of
mononuclear cell infiltration in the allografts.
As a result of AR-related myocardial muscle
damage, possibly aggravated by surgical skeletal
muscle damage, serum aspartate amino trans-
ferase concentration was elevated almost 15-fold
in the Lewis rats transplanted with a DA heart, as
compared to healthy Lewis animals [13]. Other
serum parameters, including creatinine and albu-
min, remained stable (table 1b).
Affymetrix genechip and real-time PCR
analyses of metzincins and ECM components
It should be noted that for all the analyses
performed, the native healthy DA hearts from
CsA treated animals did not show significant dif-
ference from non-treated healthy DA hearts.
Thus, for the clarity of our manuscript, exclu-
sively native DA hearts were shown as healthy
controls in our experiments.
SWISS MED WKLY 20 09 ; 139 ( 15–16 ) : 233–240 · www.smw.ch
Results
DA healthy DA graft hearts
native hearts
Cyclosporine treatment – – +
Mononuclear infiltration 0 3 2MF
Polynuclear infiltration 0 0 0
Necrosis 0 0 0
Fibrosis 0 0 0
Calcification 0 0 0
Haemorrhage 0 0–1F 0–1F
Vasculitis 0 1 1
Edema 0 0–1 0
Final grade of rejection 0 3 2
DA = Dark Agouti. Mean histological scores = 1: Slight / Minimal;
2: Moderate; 3: Marked (F: Focal; MF: Multifocal); Grade of
rejection = 0: no rejection, 2: moderate rejection, 3: marked rejec-
tion; (n = 6 in each group).
Laboratory values Healthy Non-treated,
control rejected
transplant
Creatinine concentration (mmol/L) 34 ± 2 36 ± 1.7
Urea (mmol/L) 3.5 ± 0.3 5.7 ± 0.4
Alkaline phosphatase (IU/L) 212 ± 16 194 ± 19
Alanine amino transferase (IU/L) 42 ± 3 62 ± 5
Aspartate amino transferase (IU/L) 49 ± 4 715 ± 228*
Albumin concentration (g/L) 13 ± 0.7 11 ± 0
Results of serum analyses are given in Mean ± SEM. Healthy
control: Lewis rats (n = 5); Non-treated transplant: DA-to-Lewis
rat heterotopic heart transplantation model (n = 4). * p <0.05.
Table 1a
Histological charac-
teristics and severity
of acute rejection
(Banff classification).
Table 1b
Biochemical charac-
teristics.
In untreated DA allografts (AR) 40% of the
ECM genes analyzed by microarrays were up-
regulated compared to native DA hearts (e.g., col-
lagens, laminin b2 and fibronectin). The mRNA
levels of TGFb1, MMP-7/-9/-/12-/14, ADAM17,
TIMP-1/-3 were increased, whereas MMP-11/-
16/-24 andTIMP-2 decreased (fig. 1a and supple-
mentary table). Compared to untreated allografts,
CsA lowered the mRNA levels of MMP-7,
TIMP-1/-3 and ADAM17, but augmented
MMP-11/-16/-23 mRNA levels (supplementary
table). The increased expression of ECM genes –
substrates of MMP and ADAM – in rejection was
even accentuated by CsA treatment in clear-cut
fashion.
By qRT-PCR, MMP-2 mRNA was signifi-
cantly and almost 2-fold up-regulated in AR (fig.
2a). CsA treatment reduced MMP-2 mRNA ex-
pression. These MMP-2 data do not corroborate
the array data showing no MMP-2 mRNA ex-
pression change. This was already observed and
commented by us in a previous publication [14]
and as follows: “The MMP-2 Affymetrix probeset
1369825_at is based on 3’ UTR sequence of GenBank
entry X71466. Due to alternative splicing or different
processing, this untranslated region of rat MMP-2 is
not found in GenBank entry U65656.Therefore, most
likely our two TaqMan probes detected all splice vari-
ants of rat MMP-2 and the Affymetrix probeset did
not recognize the U65656 variant of MMP-2 over-
expressed in our rat model of acute rejection”.
Furthermore, the qRT-PCR analyses showed
a very high TIMP-4 mRNA level in DA healthy
native hearts, which was decreased some 150-fold
in untreated AR compared to these controls. In
AR hearts with CsA treatment, TIMP-4 mRNA
expression was increased 13.5-fold compared to
non-treated AR hearts.
TNFa was used as a positive control for the
inflammatory response. It was confirmed that
TNFa protein levels measured by ELISA were
higher expressed in AR compared to normal
hearts (2.5 ± 0.2 pg/ml vs 1.1 ± 0.2 pg/ml); these
levels were reduced to approximately the control
levels by CsA treatment (1.0 ± 0.4 pg/ml).
MMP activity levels
As measured by fluorometry, overall MMP
activity was increased almost 2-fold in acutely re-
jected DA hearts compared to healthy control
hearts (fig. 2b). CsA did not have a significant in-
fluence.
By gelatin substrate zymography, the 92-kDa
pro-form of MMP-9 was significantly increased
(4.0-fold, p <0.05) in AR, as compared to healthy
controls (fig. 2c). MMP-9 active form was most
probably under the detection limit of the tech-
nique and thus not seen here. MMP-9 pro-form
was significantly reduced by exposure to CsA.
These observations confirmed the mRNA results
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Gene Affymetrix DA healthy Untreated DA Cyclosporine treated
probeset native hearts cardiac allografts DA cardiac allografts
Mean expression values of MMP,TIMP and ADAM
MMP-2 1369825_at 29.5 ± 3.2 27.7 ± 0.0 28.1 ± 1.4
MMP-3 1368657_at 17.7 ± 0.4 20.2 ± 4.5 16.0 ± 1.0
MMP-7 1368766_at 20.0 ± 4.0 30.5 ± 5.4* 21.3 ± 4.3
#
MMP-8 1387735_at 16.6 ± 1.6 18.8 ± 0.2 17.3 ± 2.1
MMP-9 1398275_at 20.5 ± 2.0 486.2 ± 568.2* 88.1 ± 48.8
MMP-10 1368713_at 18.1 ± 0.8 19.5 ± 1.7 24.6 ± 10.8
MMP-11 1367858_at 58.9 ± 8.0 34.3 ± 4.3* 47.8 ± 4.3
#
MMP-12 1368530_at 31.4 ± 6.7 192.5 ± 112.5* 296.0 ± 50.5
MMP-13 1388204_at 13.3 ± 0.2 15.7 ± 2.6 16.1 ± 0.6
MMP-14 1378225_at 109.3 ± 7.3 261.1 ± 25.1* 256.0 ± 46.1
MMP-16 1368590_at 17.1 ± 0.3 14.5 ± 0.7* 19.3 ± 0.7
#
MMP-23 1368961_at 63.7 ± 11.4 93.2 ± 26.8 153.3 ± 40.4
#
MMP-24 1389833_at 243.5 ± 8.6 90.0 ± 15.1* 101.5 ± 31.8
ADAM-10 1388161_at 46.2 ± 5.6 55.3 ± 22.0 30.4 ± 6.5
ADAM-17 1367922_at 502.9 ± 45.7 1237.8 ± 86.6* 767.0 ± 225.6
#
TIMP-1 1367712_at 120.0 ± 2.2 6468.3 ± 1498.2* 2616.5 ± 412.1
#
TIMP-2 1367823_at 140.7 ± 4.1 98.1 ± 18.3* 96.8 ± 17.9
TIMP-3 1368989_at 31.6 ± 4.5 50.1 ± 12.5* 29.3 ± 5.9
#
Mean expression values of ECM components
Collagen I a1 1370864_at 412.6 ± 29.2 1389.5 ± 384.3* 3829.1 ± 80.0
#
Collagen I a2 1387854_at 1269.6 ± 67.7 2221.2 ± 814.4* 7069.4 ± 304.2
#
Collagen II a1 1387767_a_at 19.8 ± 1.1 20.7 ± 7.4 31.6 ± 25.0
Collagen III a1 1370959_at 3759.2 ± 67.9 6382.6 ± 1723.4* 12640.4 ± 1381.2
#
Collagen V a1 1369955_at 126.5 ± 20.6 158.5 ± 28.1 388.9 ± 183.8
#
Collagen V a2 1370895_at 561.7 ± 41.4 814.7 ± 292.4 2961.7 ± 271.8
#
Collagen V a3 1368347_at 144.8 ± 14.8 189.6 ± 31.9* 306.0 ± 41.9
#
Collagen X a1 1370944_at 19.3 ± 2.5 17.8 ± 1.4 18.2 ± 2.3
Collagen XI a1 1384211_at 11.4 ± 0.2 11.6 ± 0.2 13.3 ± 0.8
Collagen XI a2 1389891_at 53.5 ± 1.1 51.0 ± 7.8 55.1 ± 10.6
Collagen XII a1 1370297_at 78.1 ± 7.9 216.1 ± 67.0* 127.8 ± 23.6
#
Collagen XVIII a1 1388459_at 125.0 ± 11.8 424.5 ± 110.1* 400.0 ± 75.9
Collagen XXIII a1 1393590_at 29.6 ± 3.0 33.1 ± 5.8 36.9 ± 18.5
Collagen XXVII a1 1375708_at 78.5 ± 7.3 62.9 ± 7.8* 102.2 ± 20.9
#
Laminin a3 1370538_at 23.0 ± 2.6 20.7 ± 1.1 22.7 ± 1.2
Laminin a5 1388932_at 329.1 ± 17.0 367.8 ± 118.7 331.2 ± 22.8
Laminin b2 1367880_at 3003.3 ± 187.2 374.8 ± 42.1* 1676.7 ± 298.9
#
Laminin c1 1370993_at 110.8 ± 18.1 197.1 ± 103.8 81.3 ± 32.6
#
Fibronectin 1 1370234_at 234.1 ± 40.9 1651.7 ± 495.6* 1863.9 ± 193.7
Proteoglycan 1 1370782_a_at 14.3 ± 0.7 14.6 ± 0.8 15.1 ± 2.9
Proteoglycan 2 1387633_at 21.2 ± 0.7 20.7 ± 2.9 21.8 ± 5.2
Mean expression values of cytokines
TGFb1 1370082_at 209.9 ± 28.5 752.9 ± 197.2* 383.2 ± 248.4
TNFa 1387691_at 42.5 ± 0.9 44.5 ± 4.2 42.3 ± 4.7
Rat Affymetrix GeneChip analyses of 41 genes (MMP, ADAM, ECM components, cytokines).
Affymetrix Rat Expression Array 230 2.0 GeneChip data. Numbers represent normalized mean
expression values ± SD. In bold, P <0.05. * significant compared to healthy DA native hearts.
#
significant compared to untreated DA heart grafts. n = 3 per group.
Supplementary
Table
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described above. However, it cannot be ruled out
that CsA causes a suppression of MMP-9 activity
independent of any change in gene expression.
Concurrent results for MMP-2 were less conclu-
sive, mainly due to a much lower degree of enzy-
matic activity in zymograms not allowing reliable
quantification.
MMP andTIMP protein levels
In Western blot analyses, the pro-form of
MMP-2 (72 kDa) was significantly increased in un-
treated DA grafts with AR, compared to the healthy
control hearts (1.8-fold, p <0.05) and decreased by
CsA treatment compared to the untreated DA
grafts with AR (1.4-fold, p <0.05) (fig. 3a).
As observed by zymography, the level of the
MMP-9 pro-form was strongly increased dur-
ing AR (2.9-fold; p <0.05), compared to the DA
healthy control hearts, and again had a tendency
to decrease upon CsA treatment (1.3-fold) (fig.
3b).The active forms of MMP-2/-9 remained un-
changed in all three experimental groups.
MMP-14 appeared not to be regulated in AR,
but its protein expression was strongly decreased
in DA grafts treated with CsA (2.2-fold; p <0.05)
(fig. 3c).
In accordance with the mRNA results,
TIMP-2 protein levels were decreased during the
AR process, an effect maintained by CsA (fig. 3d).
We extended the MMP-2 analyses with im-
munohistology of heart tissue sections. MMP-2
staining was visibly increased in the myocardium
of acutely rejected DA hearts. Since only the pro-
form was significantly regulated in Western blot
SWISS MED WKLY 20 09 ; 139 ( 15–16 ) : 233–240 · www.smw.ch
Figure 1
Hierarchical cluster analysis of gene expression
profiles from rat hearts. 1 = DA healthy native
hearts, 2 = Untreated DA cardiac allografts
(AR), 3 = CsA treated DA cardiac allografts.
Each column represents a sample; each row
represents a gene from the gene list of Supple-
mentaryTable.Transcripts abundance is dis-
played on a red-green colour scale, with red
expression above and green expression below
the median.The cluster dendrogram sorts the
samples based on the degree of similarity of
gene expression profiles. Based on our genes
of interest, rat samples with untreated AR can
be clearly separated from the control and CsA-
treated groups.
Figure 2
Rat heart MMP-2 mRNA expression and overall
MMP activity. (a) MMP-2TaqMan qRT-PCR
showed a significant increase of MMP-2 mRNA
expression in DA allografts compared with DA
healthy native control hearts. (b) Fluorometry
from total protein extractions showed a signifi-
cant, almost two-fold increase in overall MMP
activity in DA allografts compared with the DA
healthy native control hearts. (c) Zymography
demonstrated increased pro-MMP-9 in un-
treated DA grafts (lane 2) compared with DA
healthy native control hearts (lane 1). Pro-MMP-
9 was significantly reduced by CsA treatment
(lane 3). Purified MMP-9 was used as positive
control (lane C). *p<0.05 compared to the DA
healthy native hearts;
#
p <0.05 compared to
the DA grafts CsA-treated; n = 6 per group.
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analysis (fig. 3a), it is most probable that the im-
munohistology represents pro-MMP-2 form and
that day +5 after transplantation does not render
the active form visible. However, we cannot de-
termine to what extent the increased MMP-2
production resulted either from the cell infiltrates
or from the myocardium itself. Nevertheless, this
result was in accordance with the PCR andWest-
ern blot results. The immunosuppressant CsA re-
duced the MMP-2 signal.
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Figure 3
Rat heart MMP
protein expression.
Western blot and
densitometry analy-
ses of MMP-2 (a),
MMP-9 (b), MMP-14
(c),TIMP-2 (d) in rat
hearts.Two represen-
tative samples for
each group are
depicted. *p <0.05
compared to the DA
healthy native hearts,
#
p <0.05 compared to
the DA grafts CsA-
treated; n = 4 per
group.
Figure 4
MMP-2 immunohis-
tology in Dark Agouti
(DA) heart sections.
The increased pres-
ence of MMP-2 was
observed in the my-
ocardium of acutely
rejected DA hearts
(middle panel), as
compared to the
healthy control (left
panel). CsA reduced
acute rejection and
consequently also the
MMP-2 signal (right
panel).
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Discussion
Taken together, the results of our investiga-
tions confirmed that most of the essential MMP
and also ADAM17 were up-regulated during ex-
perimental AR of heart allografts. The important
TIMP were divergently regulated. Amongst these
key MMP inhibitors, TIMP-1 was increased and
TIMP-2 was decreased as a result of the rejection
process. It should be noted that TIMP-2 regulates
MMP-2 activity in the extracellular environment
after pro-MMP-2 activation by MMP-14. Thus,
the remaining expression of TIMP-2 in rejection
is not enough to inhibit MMP-2 activity in signifi-
cant fashion and leads to an imbalance with in-
creased MMP-2 activity. Consequently, overall
MMP activity, including MMP-9, was enhanced
in our model of allograft rejection. Furthermore,
our rat data were in principle in accordance with
human microarray data from endomyocardial
transplant biopsies recently made publicly avail-
able [15]. These expression data were obtained
from three biopsies per patient: one before AR,
one during AR and after rejection (patients under
immunosuppressant).
Alterations in the regulation of MMP and
TIMP have already been investigated in various
human and experimental cardiovascular diseases
(e.g., vascular remodelling, cardiomyopathy, etc.)
[16,17]. MMP were also shown to contribute to
atherosclerosis and to be associated with the acute
coronary syndrome, and they may thus be impor-
tant therapeutic targets for future drug develop-
ment [18]. However, in another study investigat-
ing rats with congestive heart failure, MMP-2 and
-9 were not noticeably activated [19]. The antibi-
otic tetracycline significantly inhibited collage-
nase activity in cardiomyopathic tissue [19]. Inter-
estingly, in another recent study it was suggested
that the distribution of ECM proteins and MMP
differ between the two ventricles in human hearts
in end-stage cardiomyopathies [20].
With respect to transplantation medicine,
MMP-2,-9,-14 and TIMP-1,-2 proteins were
found to be differentially expressed in different
regions of coronary vessels at different time points
of acutely rejected transplanted primate hearts
[21]. Furthermore, it was concluded that MMP-2,
TIMP-1/-2 expressions were sensitive indicators
of acute and chronic cardiac rejection, as analyzed
in myocardium and coronary arteriosclerosis in
cardiac allografts of non-human primates [22].
MMP-2 and MMP-9 were up-regulated in
another rat heart strain combination three days
after transplantation and the treatment with a spe-
cific MMP inhibitor decreased the levels of both
MMP efficiently [23]. Our results are together in
accordance with these two studies.
Since the minimum efficacious dose of CsA
was 5.0 mg/kg/day in the DA-to-Lew heart trans-
plantation model [24], the cyclosporine dose in
our study was certainly sufficient to have a poten-
tial effect on metzincins and ECM proteins. CsA
did not show a clear effect on the expression of
MMP by decreasing as well as increasing various
MMP. However, TIMP were decreased or kept
low in acute cardiac allograft rejection. CsA did
not influence overall MMP activity, though this
agent reduced the production of MMP-14 in ac-
cordance with the literature reporting that MMP-
14 mRNA expression is indeed modified by CsA
[25].
The main effect of CsA was to raise RNA lev-
els of ECM components, such as many types of
collagens and laminin. It is also likely that molec-
ular changes indicative of fibrosis precede visibly
recognizable fibrosis. In this respect, CsA showed
signs of fibrosis on the gene expression level.
However, these changes were not (yet) evident on
our histology sections. Thus, although this cal-
cineurin inhibitor showed a clear benefit in the
prevention of acute rejection, in the long run it
may contribute to organ fibrosis and sclerosis.
In our study we cannot distinguish to what ex-
tent CsA has a direct effect on MMP production
and an indirect effect via attenuation of AR. How-
ever, since the results of untreated DA native
hearts and DA CsA treated native hearts were
identical, these effects of CsA appeared to be pre-
dominantly indirect under our study conditions.
In another rat model of cardiac transplanta-
tion (Wistar Furst-to-Lewis), TGFb, collagen, fi-
bronectin, MMP-2/-9 and TIMP-2 were found to
be increased by PCR in rats treated with cy-
closporine for 180 days, compared to untreated
animals [26]. These findings are in principle con-
cordant with our results, although we used a
slightly different animal model and acute instead
of chronic treatment.
In another experimental study, the treatment
with the immunosuppressant tacrolimus had to be
supplemented by the administration of an MMP
inhibitor during 14 days to decrease the high ex-
pression of MMP-2 in a heterotopic rat heart
transplantation model [27]. Thus, for effective
MMP-inhibition, a specific MMP-inhibitor needs
to be added to an immunosuppressant regimen of
this kind.
To definitely elucidate the pathogenetic role
of metzincins in cardiac allograft rejection, inter-
ventional studies with the aim of selectively in-
hibiting individual members of this enzyme fam-
ily are needed. Besides the model of AR used in
our investigation, a more chronic experimental
transplant model (LEW to F344) may also be
used for such investigations [28].
Taken together, most MMP, TIMP and ECM
genes were up-regulated during AR in heart allo-
grafts. The short-term therapy with CsA amelio-
rated the histology of acute rejection but also
showed a potential concomitant pro-fibrotic effect,
reflected by the regulation of TIMP and ECM
proteins.Thus,MMP andTIMPmay play a role in
acute cardiac allograft rejection and beneficial
modification of the MMP-ECM balance requires
interventions beyond the application of CsA.
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